Gemcitabine plus oxaliplatin for the treatment of leptomeningeal metastases of non-small cell lung cancer: A case report and review of the literature

Bai,Chong; Shi,Hui; Liu,Dan; Zhu,Tianyi; Hu,Zhenli; Li,Qiang

doi:10.3892/ol.2013.1263

Gemcitabine plus oxaliplatin for the treatment of leptomeningeal metastases of non-small cell lung cancer: A case report and review of the literature

Authors:
- Chong Bai
- Hui Shi
- Dan Liu
- Tianyi Zhu
- Zhenli Hu
- Qiang Li
View Affiliations

Affiliations: Department of Respiratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: March 19, 2013 https://doi.org/10.3892/ol.2013.1263
Pages: 1559-1561

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A 62-year-old male presented with stage IV lung adenocarcinoma with leptomeningeal metastases (LM). Gemcitabine (1000 mg/m2 i.v.) was administered on days 1 and 8 while oxaliplatin (100/m2 i.v.) was administered on day 1 and repeated for 4 cycles every 3 weeks. Computerized tomography (CT) and cerebrospinal fluid (CSF) were used to evaluate the response of the LM and the primary tumor to drug therapy. Following the administration of chemotherapy, headaches were observed to be notably reduced 6 days later and absent after 14 days. The symptoms of coughing and chest pain were alleviated. Subsequent to 4 cycles of treatment, the patient had a partial response (PR) and the CSF pressure was normal. Analysis of the CSF revealed that it was colorless, positive for protein, had a total cell number of 0/l and contained no cancer cells. However, the primary lung tumor progressed for 1 year. This may suggest that first-line therapies, including the use of gemcitabine and oxalipaltin, may be appropriate for the treatment of non-small cell lung carcinoma (NSCLC) with LM involvement.

View Figures

View References

1	Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K and Delattre JY: Leptomeningeal metastases from solid malignancy: a review. J Neurooncol. 75:85–99. 2005. View Article : Google Scholar : PubMed/NCBI
2	Gerrard GE and Franks KN: Overview of the diagnosis and management of brain, spine, and meningeal metastases. J Neurol Neurosurg Psychiatry. 75(Suppl 2): ii37–ii42. 2004. View Article : Google Scholar : PubMed/NCBI
3	Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C and de Wit M: Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol. 136:1729–1735. 2010. View Article : Google Scholar : PubMed/NCBI
4	Twijnstra A, Ongerboer de Visser BW and van Zanten AP: Diagnosis of leptomeningeal metastasis. Clinical Neurol Neurosurg. 89:79–85. 1987. View Article : Google Scholar
5	Chuang TY, Yu CJ, Shih JY, Yang PC and Kuo SH: Cytologically proven meningeal carcinomatosis in patients with lung cancer: clinical observation of 34 cases. J Formos Med Assoc. 107:851–856. 2008. View Article : Google Scholar : PubMed/NCBI
6	Wasserstrom WR, Glass JP and Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 49:759–772. 1982. View Article : Google Scholar : PubMed/NCBI
7	Strady C, Ricciarelli A, Nasca S, Liautaud-Roger F and Coninx P: Carcinomatous meningitis and solid tumours. Oncol Rep. 7:203–207. 2000.PubMed/NCBI
8	Waki F, Ando M, Takashima A, et al: Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol. 93:205–212. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kesari S and Batchelor TT: Leptomeningeal metastases. Neurol Clin. 21:25–66. 2003. View Article : Google Scholar
10	Park JH, Kim YJ, Lee JO, et al: Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer. 76:387–392. 2012. View Article : Google Scholar : PubMed/NCBI
11	Westphal M, Heese O and de Wit M: Intracranial metastases: therapeutic options. Ann Oncol. 14(Suppl 3): iii4–iii10. 2003. View Article : Google Scholar : PubMed/NCBI
12	Chamberlain MC: Neoplastic meningitis. J Clinical Oncol. 23:3605–3613. 2005. View Article : Google Scholar : PubMed/NCBI
13	Ahmed SA, Gogal RM Jr and Walsh JE: A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods. 170:211–224. 1994.PubMed/NCBI
14	Paydas S, Bicakci K and Yavuz S: Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer. Eur J Intern Med. 20:96–99. 2009. View Article : Google Scholar : PubMed/NCBI
15	Chen YM, Chen MC, Tsai CM and Perng RP: Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis - a case report. Lung Cancer. 40:99–101. 2003. View Article : Google Scholar : PubMed/NCBI
16	Sakai M, Ishikawa S, Ito H, et al: Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. Int J Clin Oncol. 11:243–245. 2006. View Article : Google Scholar : PubMed/NCBI
17	Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
18	Choong NW, Dietrich S, Seiwert TY, et al: Gefitinib response of erlotinib-refractory lung cancer involving meninges - role of EGFR mutation. Nat Clin Pract Oncol. 3:50–57. 2006. View Article : Google Scholar : PubMed/NCBI
19	Jackman DM, Holmes AJ, Lindeman N, et al: Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 24:4517–4520. 2006. View Article : Google Scholar : PubMed/NCBI
20	Clarke JL, Pao W, Wu N, Miller VA and Lassman AB: High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 99:283–286. 2010. View Article : Google Scholar